Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Kinnate is the latest Raf player to trip up
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
